Saturday 17 October 2026
Export NBIX’s income statement to Excel — free account
Neurocrine Biosciences, Inc.
NBIX Healthcare Drug Manufacturers Specialty & Generic
Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024. In the quarter to June 2026, revenue grew 39.5%, EPS grew 31.2% and free cash flow grew 43.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for five.
135.71
1.24
−0.91%
Follow NBIX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
7 | 8 | 6 | 6 | 4 | 5 | 7 | 6 | 3 | — |
P/E ratio |
29.43 | 40.38 | 51.86 | 74.58 | 89.65 | 21.98 | 268.73 | 324.59 | 0.00 | 0.00 |
P/S ratio |
4.93 | 5.82 | 6.82 | 7.73 | 7.11 | 8.53 | 12.49 | 14.28 | 39.55 | 92.53 |
Altman Z-Score |
7.80 | 8.83 | 8.70 | 11.59 | 7.62 | 9.70 | 8.65 | 7.24 | 7.56 | 35.68 |
Altman Z″-Score (non-manufacturers) |
6.21 | 5.61 | 4.58 | 5.40 | 3.70 | 4.35 | (0.12) | 1.66 | (0.97) | (0.53) |
P/FCF ratio |
18.85 | 24.60 | 35.59 | 35.63 | 34.56 | 41.01 | 74.42 | 84.09 | 0.00 | 0.00 |
Beneish M-Score |
(2.64) | (2.23) | (1.68) | (2.15) | (2.60) | (1.55) | (1.75) | (1.52) | — | — |
P/Operating CF |
36.33 | 56.51 | 104.21 | 80.45 | 1,918.35 | 94.43 | 100.99 | 127.57 | 172.16 | (106.00) |
P/B ratio |
4.34 | 5.29 | 5.77 | 6.74 | 5.86 | 7.92 | 15.46 | 13.40 | 18.77 | 10.65 |
Price to Tangible BV |
4.35 | 5.37 | 5.86 | 6.89 | 5.86 | 7.92 | 15.46 | 13.40 | 18.77 | 10.65 |
EV/Sales |
4.61 | 5.60 | 6.57 | 7.38 | 7.11 | 8.44 | 12.24 | 14.54 | 38.72 | 84.07 |
EV/EBITDA |
20.71 | 23.07 | 48.80 | 40.97 | 58.40 | 45.72 | 96.46 | 109.92 | 0.00 | 0.00 |
EV/Operating CF |
16.85 | 22.14 | 31.78 | 32.39 | 31.44 | 38.62 | 65.62 | 64.72 | (72.50) | (28.69) |
EV/FCF |
17.61 | 23.66 | 34.27 | 34.04 | 34.60 | 40.55 | 72.91 | 85.67 | (67.54) | (27.62) |
Quick Ratio |
2.92 | 3.06 | 2.25 | 2.49 | 3.65 | 5.14 | 1.41 | 8.03 | 10.05 | 10.11 |
Current Ratio |
3.39 | 3.40 | 2.45 | 2.70 | 3.96 | 5.45 | 1.47 | 8.36 | 10.20 | 10.21 |
Net Debt/EBITDA |
(2.33) | (1.88) | (4.06) | (3.69) | (2.72) | (2.50) | (5.83) | (4.40) | 1.27 | 2.15 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 16.17% | 18.33% | 6.66% | 39.12% | 45.21% | 0.17% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.24 | 0.28 | 0.14 | 0.81 | 0.99 | 0.00 |
Asset Turnover |
0.69 | 0.68 | 0.67 | 0.67 | 0.60 | 0.69 | 0.69 | 0.50 | 0.27 | 0.04 |
Operating CF/Net income |
1.64 | 1.74 | 1.56 | 2.20 | 2.86 | 0.56 | 3.97 | 4.81 | 0.66 | 0.75 |
Capex/Depreciation |
(1.95) | (42.44) | (9.43) | (0.85) | (0.66) | (0.36) | (0.53) | (1.08) | (0.43) | (0.82) |
Interest Coverage |
— | — | 54.54 | 35.07 | 3.97 | 4.97 | 2.26 | 1.21 | (6.73) | (49.12) |
| 16.38% | 14.16% | 12.68% | 10.03% | 7.17% | 46.20% | 6.62% | 4.95% | (41.50%) | (38.17%) | |
| 11.46% | 9.79% | 8.89% | 6.96% | 4.71% | 26.79% | 3.22% | 2.33% | (24.10%) | (33.60%) | |
ROIC |
21.83% | 23.56% | 13.06% | 21.66% | 6.42% | 15.84% | 84.62% | 10.53% | (36.36%) | (1,130.99%) |
Return on Tangible Assets |
25.61% | 26.26% | 24.41% | 15.86% | 11.41% | 46.59% | 12.03% | 3.09% | (27.88%) | (49.28%) |
Average Days of Receivables |
87.64 | 74.25 | 84.97 | 85.81 | 59.73 | 54.83 | 58.63 | 46.44 | 70.29 | 0.00 |
Research and Development Expense of Revenue |
35.51% | 31.04% | 29.94% | 31.15% | 28.95% | 26.29% | 25.38% | 34.53% | 56.81% | 628.61% |
Selling, General and Administrative Expense of Revenue |
40.42% | 42.76% | 47.04% | 50.56% | 51.46% | 41.43% | 44.93% | 55.16% | 105.12% | 453.87% |
Intangible Assets out of Total Assets |
0.00 | 0.01 | 0.01 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
7.62% | 8.30% | 10.30% | 11.63% | 11.84% | 9.56% | 9.55% | 12.88% | 26.31% | 189.76% |
Graham Net Nets |
0.08 | 0.04 | 0.05 | 0.07 | 0.03 | 0.05 | 0.02 | 0.04 | 0.02 | 0.08 |
Graham Number |
59.55 | 44.29 | 36.13 | 25.41 | 17.62 | 34.45 | 7.91 | 5.14 | 0.00 | 0.00 |
Earnings Yield |
3.40% | 2.48% | 1.93% | 1.34% | 1.12% | 4.55% | 0.37% | 0.31% | (2.06%) | (4.19%) |
Free Cash Flow Yield |
5.31% | 4.07% | 2.81% | 2.81% | 2.89% | 2.44% | 1.34% | 1.19% | (1.45%) | (3.29%) |
Revenue per Share |
28.75 | 23.46 | 19.32 | 15.54 | 11.98 | 11.23 | 8.60 | 5.00 | 1.83 | 0.17 |
Operating CF per Share |
7.87 | 5.93 | 3.99 | 3.54 | 2.71 | 2.45 | 1.60 | 1.12 | (1.07) | (1.22) |
Capex per Share |
(0.34) | (0.38) | (0.29) | (0.17) | (0.25) | (0.12) | (0.16) | (0.27) | (0.08) | (0.05) |
Free Cash Flow per Share |
7.52 | 5.55 | 3.70 | 3.37 | 2.46 | 2.34 | 1.44 | 0.85 | (1.15) | (1.27) |
Cash per Share |
14.88 | 10.72 | 10.56 | 10.33 | 7.52 | 8.60 | 7.32 | 7.22 | 5.86 | 3.54 |
Shareholders Equity per Share |
32.69 | 25.79 | 22.85 | 17.83 | 14.52 | 12.10 | 6.95 | 5.33 | 4.22 | 3.63 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
32.69 | 25.79 | 22.85 | 17.83 | 14.52 | 12.10 | 6.95 | 5.33 | 4.22 | 3.63 |
Free Cash Flow |
748.70 | 557.20 | 361.60 | 322.90 | 233.10 | 217.60 | 132.30 | 76.60 | (101.26) | (110.28) |
Working Capital |
1,779.30 | 1,217.00 | 952.20 | 915.80 | 727.00 | 829.70 | 265.70 | 649.54 | 500.49 | 280.03 |
Capital Expenditures |
(34.00) | (38.20) | (28.30) | (16.50) | (23.40) | (10.90) | (14.70) | (24.80) | (6.93) | (4.09) |
Net Current Asset Value |
1,144.30 | 595.70 | 587.60 | 792.60 | 274.30 | 407.70 | 161.90 | 225.39 | 109.47 | 260.23 |
EV/EBIT |
21.30 | 23.11 | 49.39 | 44.14 | 78.68 | 54.14 | 133.42 | 178.33 | 0.00 | 0.00 |
Capex to Sales |
0.01 | 0.02 | 0.02 | 0.01 | 0.02 | 0.01 | 0.02 | 0.06 | 0.04 | 0.27 |
Price to Operating Income |
22.79 | 24.02 | 51.30 | 46.20 | 78.61 | 54.75 | 136.18 | 175.03 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.19 | 0.01 | 0.04 | 0.33 | 0.61 | 0.67 | 0.66 | 0.68 | 1.47 | 0.79 |
Cash ROIC |
15.82% | 15.20% | 11.08% | 11.97% | 9.63% | 9.69% | 9.49% | 5.04% | (8.05%) | (17.71%) |
Accounts Receivable Turnover |
4.91 | 5.13 | 4.78 | 5.56 | 6.62 | 7.37 | 8.57 | 10.19 | 7.15 | 0.00 |
Accounts Payable Turnover |
0.09 | 0.07 | 0.10 | 0.08 | 0.07 | 0.07 | 0.07 | 0.07 | 0.03 | 0.00 |
Inventory Turnover |
0.82 | 0.71 | 1.08 | 0.71 | 0.49 | 0.45 | 0.53 | 0.82 | 0.21 | — |
Average Days of Payables |
4,723.98 | 4,955.41 | 4,126.25 | 5,468.71 | 5,763.43 | 6,096.58 | 6,969.53 | 6,434.21 | 15,577.99 | 0.00 |
Days of Inventory on Hand |
483.40 | 616.21 | 352.13 | 552.22 | 778.50 | 1,011.88 | 853.31 | 809.26 | 298.05 | — |
Average Receivables |
582.95 | 459.20 | 394.65 | 267.75 | 171.30 | 141.85 | 92.00 | 44.27 | 22.61 | — |
Average Payables |
567.95 | 455.20 | 398.20 | 286.70 | 197.25 | 155.00 | 113.84 | 69.95 | 39.85 | 14.37 |
Average Inventory |
63.20 | 47.85 | 36.70 | 32.80 | 29.25 | 22.65 | 14.08 | 5.94 | 6.01 | — |
Average Assets |
4,175.10 | 3,485.05 | 2,810.05 | 2,220.60 | 1,903.60 | 1,520.35 | 1,149.58 | 905.37 | 591.34 | 419.94 |
Average Common Equity |
2,921.40 | 2,410.85 | 1,969.90 | 1,540.90 | 1,250.10 | 881.55 | 558.83 | 426.45 | 343.51 | 369.67 |
Columns are period end dates